Rift Valley Fever Clinical Trial
Official title:
Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
Study Objectives:
The objectives of this two-part, primary immunization and booster dose, study are to continue
to collect safety data on Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200); and, to
continue to collect immunogenicity data on Rift Valley Fever (RVF) Vaccine, Inactivated
(TSI-GSD 200) and analyze interim data to determine whether a 6-month dose is indicated; and,
to provide potential protection for personnel at risk for occupational exposure to the RVF
virus and collect data on incidence of occupational RVF infection (subclinical and clinical)
in immunized personnel.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00869713 -
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
|
Phase 2 | |
| Recruiting |
NCT05139524 -
RVF and Other Emerging Infectious Diseases in East and Central Africa
|
||
| Recruiting |
NCT03609398 -
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
|
Phase 2 | |
| Completed |
NCT04672824 -
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00287014 -
Rift Valley Fever in Kenya
|
N/A | |
| Completed |
NCT04754776 -
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
|
Early Phase 1 | |
| Completed |
NCT00415051 -
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
|
Phase 2 |